SCHEMBL21044154

SCHEMBL21044154

N#Cc1cncc(-c2ccc(N)cc2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 7/20 0.56
CYP11B1 P15538 6/20 0.56
FYN P06241 1/20 0.40
IRAK4 Q9NWZ3 1/20 0.40
CHEK1 O14757 1/20 0.38
METAP2 P50579 1/20 0.38
PRKCZ Q05513 1/20 0.38
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.37
HPGD P15428 2/20 0.37
GLA P06280 2/20 0.37
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37
GFER P55789 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SCN2A Q99250 1/20 0.36
SCN10A Q9Y5Y9 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21044477 0.82 CYP11B1 (0.42) CYP11B2CYP11B1FYNMETAP2PRKCZ
SCHEMBL8070286 0.81 CYP11B2 (0.55) CYP11B2CYP11B1IRAK4MEN1KMT2A
SCHEMBL21044544 0.81 CYP11B2 (0.52) CYP11B2CYP11B1IRAK4MEN1KMT2A
SCHEMBL30461137 0.80 FYN (0.49) CYP11B2FYNCHEK1METAP2PRKCZ
SCHEMBL28145764 0.80 CYP11B1 (0.55) CYP11B2CYP11B1FYNIRAK4METAP2
SCHEMBL21044075 0.78 CYP11B2 (0.56) CYP11B2CYP11B1IRAK4ALDH1A1MAPT
SCHEMBL22869136 0.78 CYP11B2 (0.72) CYP11B2CYP11B1IRAK4
SCHEMBL21044251 0.77 FYN (0.40) CYP11B2CYP11B1FYNMETAP2PRKCZ
SCHEMBL22869135 0.76 FYN (0.39) CYP11B2CYP11B1FYNMETAP2PRKCZ
SCHEMBL30338462 0.74 CYP11B2 (0.51) CYP11B2CYP11B1METAP2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3717459-B1 COMPOUNDS STEP PHARMA S A S (FR) 2026-01-21 EP disclosed
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2023-05-23 US disclosed
US-20210002269-A1 COMPOUNDS STEP PHARMA S.A.S. (FR) 2021-01-07 US disclosed
EP-3492454-A1 COMPOUNDS Step Pharma S.A.S. (FR) 2019-06-05 EP disclosed
EP-3492454-A1 COMPOUNDS Step Pharma S.A.S. (FR) 2019-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 CTPS1, CTPS2, TBXAS1 CYP11B2 1869/4885CYP11B1 1418/4885FYN 4874/4885
US-20210002269-A1 COMPOUNDS UGT1A1, CYP1A1, CYP19A1 CYP11B2 6/4885CYP11B1 5/4885FYN 3915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.